The Apolipoprotein A pipeline drugs market research report outlays comprehensive information on the Apolipoprotein A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Apolipoprotein A pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Metabolic Disorders, Genito Urinary System, and Ophthalmology which include the indications Atherosclerosis, Unspecified Cardiovascular Disorders, Hyperlipidemia, Hypercholesterolemia, Kidney Disease (Nephropathy), and Uveitis. It also reviews key players involved in Apolipoprotein A targeted therapeutics development with respective active and dormant or discontinued products.
The Apolipoprotein A pipeline targets constitutes close to 14 molecules. Out of which, approximately 13 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 2, 3, 3, 3, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Apolipoprotein A overview
Apolipoprotein A-I is the main protein component of the high-density lipoproteins (HDL) that circulate collecting cholesterol from tissues and delivering it to the liver. The encoded preproprotein is proteolytically processed to generate the mature protein, which promotes cholesterol efflux from tissues to the liver for excretion and is a cofactor for lecithin cholesterolacyltransferase (LCAT), an enzyme responsible for the formation of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on chromosome 11. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis.
For a complete picture of Apolipoprotein A’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
